continua IL black FRIDAY al CUBO |15% su tutto con il coupon 15alcubo | SCOPRI di più

Customer care
  • Vectavir Labiale 1% Cream 2g -43%

Vectavir Labiale 1% Cream 2g

7.18€ 12.50€
  • Purchase 3 items for 7.04€ each
  • Purchase 4 items for 6.89€ each
  • Purchase 5 items for 6.75€ each

Vectavir for the treatment of cold sores 1% cream

Active principles

Each gram of cream contains 10 mg of penciclovir Excipients with known effects: 77.2 mg of cetostearyl alcohol, 416.8 mg of propylene glycol. For the full list of excipients, see section 6.1.

Excipients

Solid paraffin Liquid paraffin Cetostearyl alcohol Propylene glycol Cetomacrogol 1000 Red iron oxide (E-172) Yellow iron oxide (E-172) Purified water
Therapeutic indications

Contraindications / Undesirable Effects

Hypersensitivity to the active substance, famciclovir or to any of the excipients listed in section 6.1. Children under the age of 12.

Dosage

Adults (including the elderly) and children over 12 years of age VECTAVIR LABIALE should be applied at intervals of approximately 2 hours throughout the day. Treatment, to be continued for 4 days, should be started as soon as possible, at the first sign of infection. However, even in patients who start therapy later, LABIAL VECTAVIR has been shown to be effective in accelerating wound healing, reducing pain associated with wounds and shortening the time to viral spread.

Pediatric population Children (below 12 years of age) VECTAVIR LABIAL is not recommended for use in children below 12 years of age due to a lack of data on safety and / or efficacy.

storage

Do not freeze. Do not store the medicine packaged in the 2g aluminum tube at temperatures above 25 ° C. Do not store medicines packaged in the 2g plastic bottle with dispenser and in the 5g aluminum tube at temperatures above 30 ° C.

Warnings

The cream should only be applied to the lesions of the lips and around the mouth. It is not recommended for application on mucous membranes (e.g. in the eyes, mouth or nose or on the genitals). Particular care should be taken to avoid application in or near the eyes. Severely immunocompromised patients (eg patients with AIDS or who have undergone a bone marrow transplant) should be encouraged to consult a physician if oral therapy is indicated. VECTAVIR LABIAL contains cetostearyl alcohol: it can cause local skin reactions (eg contact dermatitis). VECTAVIR LABIAL contains propylene glycol: can cause skin irritation.

Interactions

Experience in clinical trials has not identified interactions resulting from the concomitant administration of topical or systemic drugs and VECTAVIR LABIALE cream.

Side effects

Post-marketing surveillance revealed the following adverse events (all reactions were either localized or general). It is difficult to define a frequency for post-marketing adverse events and therefore the events are listed with an unknown frequency.
Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http://www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa

Overdose

Even after oral ingestion of the entire contents of a pack of VECTAVIR LABIALE cream, no undesirable effects should occur; penciclovir is poorly absorbed after oral administration. However, oral irritation may occur. In case of accidental ingestion, no specific treatment is necessary.

Pregnancy and breastfeeding

Pregnancy When the cream is used in pregnant women, there is unlikely to be any cause for concern about adverse effects as systemic absorption of penciclovir following topical application of VECTAVIR LABIAL cream was found to be minimal (see Section 5.2). . As the safety of penciclovir in pregnant women has not been established, VECTAVIR LABIAL cream should be used on the advice of a physician during pregnancy or by mothers who are breastfeeding, only if the potential benefits outweigh the potential risks associated with treatment. Breastfeeding When the cream is used in women who are breastfeeding, there is unlikely to be any cause for concern about adverse effects as systemic absorption of penciclovir following topical application of VECTAVIR LABIAL cream was found to be minimal (see Section 5.2 There is no information on the excretion of penciclovir in human milk.

Format

2g tube.

.